Strategies to enhance the likelihood of detecting true effects in randomised controlled trials

Kelly D Spreafico A Siu LL. Increasing operational and scientific efficiency in clinical trials. Br J Cancer 2020; 12: 1207–1208. doi:10.1038/s41416-020-0990-8

Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. Contemp Clin Trials Commun 2018; 11: 156–164. doi:10.1016/j.conctc.2018.08.001

US Food and Drug Administration. U.S. Food and Drug Administration Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. Enrichment strategies for clinical trials to support determination of effectiveness of human drugs and biological products, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enrichment-strategies-clinical-trials-support-approval-human-drugs-and-biological-products (2019, accessed 10 June 2025).

Bitonti TM Durr KM Fernando SM , et al. Randomized controlled trials for the prevention of venous thromboembolism in critically ill patients: A systematic review of sample size methodologies. Anaesth Intensive Care. Epub ahead of print Dec 2025. doi:10.1177/0310057X251397167.

Ho KM. Importance of the baseline risk in determining sample size and power of a randomized controlled trial. J Emerg Crit Care Med 2018; 2: 70. doi:10.21037/jeccm.2018.08.06

Ho KM Holley A Lipman J. Vena Cava filters in severely-injured patients: One size does not fit all. Anaesth Crit Care Pain Med 2019; 38: 305–307. doi:10.1016/j.accpm.2019.07.003

Li Y Lai D Li R , et al. A biomarker signature-guided clinical trial design for precision medicine. Stat Med 2025; 44: e70103. doi:10.1002/sim.70103

Ostrowski SM Fisher DE. Biology of melanoma. Hematol Oncol Clin North Am 2021; 35: 29–56. doi:10.1016/j.hoc.2020.08.010

Thorlund K Haggstrom J Park JJ , et al. Key design considerations for adaptive clinical trials: a primer for clinicians. BMJ 2018; 360: k698. doi:10.1136/bmj.k698

Zhao Y Li D Liu R , et al. Bayesian optimal phase II designs with dual-criterion decision making. Pharm Stat 2023; 22: 605–618. doi:10.1002/pst.2296

Ho KM Lee A. Using Bayesian hypothesis-testing to reanalyze randomized controlled trials: Does it always tell the truth, the whole truth and nothing but the truth? Indian J Crit Care Med 2024; 28: 1005–1008. doi:10.5005/jp-journals-10071-24833

Teede HJ Best K Bloomfield FH , et al. Implementability and impact in clinical research and the role of clinical trial networks. Med J Aust 2024; 221: 410–413. doi:10.5694/mja2.52444

Collins MG Fahim MA Pascoe EM , et al; BEST-Fluids Investigators; Australasian Kidney Trials Network. Balanced crystalloid solution versus saline in deceased donor kidney transplantation (BEST-Fluids): A pragmatic, double-blind, randomised, controlled trial. Lancet 2023; 402: 105–117. doi:10.1016/S0140-6736(23)00642-6